Cardiac effects of hyperprolactinemiatherapy withdopamine agonists

Authors

  • Ю. В. Давыдова Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine, Ukraine
  • А. Ю. Лиманская Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine, Ukraine
  • Т. В. Волошина BMY SBU, Ukraine
  • Л. Е. Костромина BMY SBU, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2012.6.50-54

Keywords:

hyperprolactinemia, dopamine agonists, Parkinson’s disease, cabergoline

Abstract

A number of publications of the 1990s found an association between the development of disease of the heart valves and the use of dopamine agonists in patients receiving treatment for Parkinson’s disease. Therefore, it became necessary to investigate the possible risks of valve disease in patients with hyperprolactinemia receiving treatment with dopamine agonists, in order to improve the recommendations.

Author Biographies

Ю. В. Давыдова, Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine

MD, head of the department of obstetric problems extragenital

А. Ю. Лиманская, Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine

Ph.D., Senior Researcher Branch obstetrical problems extragenital Department

Т. В. Волошина, BMY SBU

MD, Head of obstetric and gynecological surgeries department

Л. Е. Костромина, BMY SBU

Obstetrician-gynecologist of the highest category

References

  1. Ling L.H, Ahlskog J.E., MungerT.M., Limper A.H., Oh J.K. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson’s disease. Mayo Clin Proc 1999. 74 : 371-375.
  2. Van Camp G., Flamez A., Cosyns B. et al. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004. 363: 1179-1183.
  3. Antonini A., Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet 2007. Neurol. 6: 826-829.
  4. Flowers C.M., Racoosin J.A., Lu S.L., Beitz J.G. The U.S. Food and Drug Administration’s Registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc. 2003 78: 730-731.
  5. FDA Public Health Advisory: pergolide. March 29, 2007. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051192.htm
  6. Andersohn F., Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot- and nonergot-derived dopamine agonists. Mov. Disord. 2009. 24: 129-133.
  7. Nebigil C.G., Choi D.S., Dierich A. et al. Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci USA. 2000. 97: 9508-9513.
  8. Lin Z., Walther D., Yu X.Y., Drgon T., Uhl G.R. The human serotonin receptor 2B: coding region polymorphisms andassociation with vulnerability to illegal drug abuse. Pharmacogenetics. 2004. 14: 805-811.
  9. Kars M. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol. 2008.159: 363-367.
  10. Bogazzi F., Manetti L., Raffaelli V. et al. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest. 2008. 31: 1119-1123.
  11. Klibanski A. Dopamine agonist therapy in prolactinomas: when can treatment be discontinued? J Clin Endocrinol Metab. 2009. 94: 2247-2249.
  12. Colao A., Galderisi M., Di Sarno A. et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 2008. 93: 3777-3784.
  13. Heart Valve Disease among Patients with Hyperprolactinemia: A Nationwide Population-Based Cohort Study.J. Clin. Endocrinol. Metab. 2012. 97: 1629-1634.
  14. Molitch M.E. The cabergoline-resistant prolactinoma patient: new challenges. J Clin Endocrinol Metab. 2008. 93:4 643-4645.
  15. Trifirò G. et al. Risk of Cardiac Valve Regurgitation with Dopamine Agonist use in Parkinson’s Disease and Hyperprolactinaemia: A Multi-Country, Nested Case-Control Study. Drug Safety:1 February 2012, Volume 35, Issue 2, 159-171.
  16. Cosyns B., Droogmans S., Rosenhek R., Lancellotti P. Drug-induced valvular heart disease Heart. 2012 Aug. 8.

Downloads

Published

2012-08-14

How to Cite

Давыдова, Ю. В., Лиманская, А. Ю., Волошина, Т. В., & Костромина, Л. Е. (2012). Cardiac effects of hyperprolactinemiatherapy withdopamine agonists. REPRODUCTIVE ENDOCRINOLOGY, (6), 50–54. https://doi.org/10.18370/2309-4117.2012.6.50-54

Issue

No. 6 (2012)

Section

Endocrine gynecology

License

Copyright (c) 2014 Ю. В. Давыдова, А. Ю. Лиманская, Т. В. Волошина, Л. Е. Костромина

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.